LENSAR (LNSR) Competitors

LENSAR (NASDAQ:LNSR) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.

Does the MarketBeat Community favor LNSR or LUNG?

Pulmonx received 28 more outperform votes than LENSAR when rated by MarketBeat users. Likewise, 45.21% of users gave Pulmonx an outperform vote while only 38.46% of users gave LENSAR an outperform vote.

Company	Underperform	Outperform
LENSAR	Outperform Votes 5 38.46%	Underperform Votes 8 61.54%
Pulmonx	Outperform Votes 33 45.21%	Underperform Votes 40 54.79%

Does the media refer more to LNSR or LUNG?

In the previous week, Pulmonx had 7 more articles in the media than LENSAR. MarketBeat recorded 10 mentions for Pulmonx and 3 mentions for LENSAR. Pulmonx's average media sentiment score of 0.38 beat LENSAR's score of 0.00 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENSAR	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulmonx	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals believe in LNSR or LUNG?

40.2% of LENSAR shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 38.5% of LENSAR shares are held by company insiders. Comparatively, 5.7% of Pulmonx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has preferable valuation and earnings, LNSR or LUNG?

LENSAR has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than LENSAR, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$42.16M	1.48	-$14.38M	-$1.56	-3.45
Pulmonx	$68.68M	3.57	-$60.84M	-$1.47	-4.27

Which has more volatility & risk, LNSR or LUNG?

LENSAR has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.

Do analysts recommend LNSR or LUNG?

LENSAR currently has a consensus target price of $8.00, indicating a potential upside of 48.70%. Pulmonx has a consensus target price of $14.67, indicating a potential upside of 133.92%. Given Pulmonx's higher probable upside, analysts clearly believe Pulmonx is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Pulmonx	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Is LNSR or LUNG more profitable?

LENSAR has a net margin of -27.83% compared to Pulmonx's net margin of -72.01%. LENSAR's return on equity of -30.69% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	-27.83%	-30.69%	-14.35%
Pulmonx	-72.01%	-51.92%	-33.27%

Summary

Pulmonx beats LENSAR on 10 of the 17 factors compared between the two stocks.